Research · Sep 3, 2026
[BMRN] BioMarin Pharmaceutical Thesis 2026: Voxzogo Achondroplasia Drives Roctavian Hemophilia Pipeline
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) FY2025 revenue ~$3.05-3.20B (+15-22%) with adj. EPS ~$3.85-4.20 reflecting continued post-2024 ~$870-925M aggregate Voxzogo (vosoritide; achondroplasia) revenue (~28%+ aggregate revenue mix; selected primary post-November 2021 EU + FDA approval) + selected continued post-2024 ~$1.85-1.95B aggregate Legacy enzyme replacement therapy (ERT) + small-molecule revenue (~62% aggregate revenue mix; selected primary Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) + selected continued post-2024 ~$310-360M aggregate Roctavian + selected various aggregate Other (~10% aggregate revenue mix) under continued President + CEO Alexander Hardy since November 2023 (~2-year tenure as BioMarin CEO). US specialty rare genetic disease biopharmaceutical company. Founded 1997 as BioMarin Pharmaceutical by Christopher Starr + Daniel Soubre + Henry Fuchs in Novato California (~28-year heritage); selected post-1999 NASDAQ IPO; selected post-November 2021 EU + FDA approval (Voxzogo for achondroplasia); selected post-August 2022 EU + post-June 2023 FDA approval (Roctavian for severe hemophilia A); selected post-November 2023 Alexander Hardy CEO appointment. Headquartered in San Rafael California; ~3,500-3,800+ employees globally with ~$3.05-3.20B revenue. One primary business: rare genetic disease biopharmaceutical (~100%). Structure: Voxzogo (~28%+ ~$870-925M), Legacy ERT (~62% ~$1.85-1.95B), Roctavian + Other (~10% ~$310-360M). Geographic mix: US ~50%+ + International ~50%. Voxzogo achondroplasia franchise: ~$870-925M Voxzogo revenue; ~+30-40% Voxzogo growth; ~5,500-6,500 aggregate cumulative patients on therapy; selected projected post-2027 ~$1.5-2B Voxzogo peak revenue. Roctavian hemophilia + ERT legacy + post-2024 portfolio rationalization: ~$1.85-1.95B Legacy ERT (Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq); ~$310-360M Roctavian + Other; ~$200-300M aggregate annual Roctavian commercial scale-up loss. President + CEO Alexander Hardy since November 2023 (~2-year tenure); CFO Brian Mueller. Capital position: ~$0 dividend (no dividend track post-1999 NASDAQ IPO); ~$300-500M aggregate FY2024-2025 buyback program (~$200-300M aggregate FY2025); ~$1.5-1.7B aggregate cash + investments balance; net leverage ratio ~negligible (~debt-free balance sheet); non-investment grade Ba2/BB+ credit rating. FY2026 thesis: Voxzogo achondroplasia franchise (~+30-40% growth) + Roctavian hemophilia commercial scale-up + ERT legacy + selected post-2024 portfolio rationalization + ~$200-300M aggregate annual buybacks + selected projected post-2026 Hypochondroplasia Phase 3 readout label expansion. Risks: Tyra Biosciences + Ascendis Pharma + Sanofi achondroplasia competition, Sangamo + Pfizer + Biogen severe hemophilia A gene therapy competition, Voxzogo eligibility expansion considerations, Roctavian commercial launch slower-than-expected.